Home›Stock Screener›Natco Pharma›Intrinsic Value

Natco Pharma Intrinsic Value

Natco Pharma intrinsic value. Natco Pharma (NATCOPHARM) median intrinsic value is ₹1643.90 from 10 valuation models (range ₹247–₹2055), vs current price ₹821.95 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Browse NATCOPHARM financial statements for revenue, profit, balance sheet and cash flow data.

Market Price (CMP)
₹821.95
Primary Intrinsic Value
₹995.28
Market Cap
₹2959 Cr
+100.0% Upside
Median Value
₹1643.90
Value Range
₹247 - ₹2055
Assessment
Trading Below Calculated Value
Safety Margin
50.0%

NATCOPHARM Valuation Methods Summary — DCF, Graham Number & P/E

Natco Pharma intrinsic value across 10 models vs current price ₹821.95 — upside/downside and value range per method. Analyse NATCOPHARM promoter holding to track promoter, FII and institutional holdings.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹995.28 ₹796.22 - ₹1194.34 +21.1% EPS: ₹45.24, Sector P/E: 22x
Book Value Method asset ₹2054.88 ₹1849.39 - ₹2260.37 +150.0% Book Value/Share: ₹2561.39, P/B: 2.0x
Revenue Multiple Method revenue ₹1643.90 ₹1479.51 - ₹1808.29 +100.0% Revenue/Share: ₹1132.22, P/S: 2.0x
EBITDA Multiple Method earnings ₹1643.90 ₹1479.51 - ₹1808.29 +100.0% EBITDA: ₹1240.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹2054.88 ₹1643.90 - ₹2465.86 +150.0% CF Growth: 15.0%, Discount: 15%
PEG Ratio Method growth ₹289.54 ₹260.59 - ₹318.49 -64.8% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹698.96 ₹629.06 - ₹768.86 -15.0% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹1643.90 ₹1479.51 - ₹1808.29 +100.0% ROE: 8.8%, P/E Multiple: 10x
Graham Defensive Method conservative ₹1614.69 ₹1453.22 - ₹1776.16 +96.4% EPS: ₹45.24, BVPS: ₹2561.39
Dividend Yield Method dividend ₹246.59 ₹221.93 - ₹271.25 -70.0% DPS: ₹5.00, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

NATCOPHARM Intrinsic Value vs Market Price — All Valuation Models

Natco Pharma fair value range ₹247–₹2055 vs current market price ₹821.95 across 10 valuation models. For current market price and key ratios, visit Natco Pharma screener.

NATCOPHARM Intrinsic Value Analysis — Undervalued or Overvalued?

Natco Pharma median intrinsic value ₹1643.90, current price ₹821.95 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.

What is the intrinsic value of NATCOPHARM?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Natco Pharma (NATCOPHARM) is ₹1643.90 (median value). With the current market price of ₹821.95, this represents a +100.0% variance from our estimated fair value.

The valuation range spans from ₹246.59 to ₹2054.88, indicating ₹246.59 - ₹2054.88.

Is NATCOPHARM undervalued or overvalued?

Based on our multi-method analysis, Natco Pharma (NATCOPHARM) appears to be trading below calculated value by approximately 100.0%.

NATCOPHARM Financial Health — Key Ratios vs Industry Benchmarks

Natco Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 8.8% Industry Standard: 15%+ Below 10% Measures shareholder return efficiency
Operating Margin 27.0% Industry Standard: 20%+ Above 20% Indicates operational efficiency level
Asset Turnover Ratio 0.37x Industry Standard: 1.0x+ Below 0.5x Measures asset utilization efficiency

NATCOPHARM Cash Flow Quality — Operating & Free Cash Flow

Natco Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹1,768 Cr ₹775 Cr Positive Free Cash Flow 7/10
March 2025 ₹1,697 Cr ₹979 Cr Positive Free Cash Flow 8/10
March 2024 ₹1,212 Cr ₹699 Cr Positive Free Cash Flow 8/10
March 2023 ₹849 Cr ₹617 Cr Positive Free Cash Flow 8/10
March 2022 ₹47 Cr ₹47 Cr Positive Free Cash Flow 8/10